by Medical University of ViennaAlzheimer's disease: patients exhibit changes in certain blood lipids that are typical of premature ageing. Credit: Medical University of ViennaThe neurodegener
by Medical University of ViennaAlzheimer's disease: patients exhibit changes in certain blood lipids that are typical of premature ageing. Credit: Medical University of ViennaThe neurodegener
by Northwestern UniversityThe recent ability to peer into the brain of living individuals with a rare type of language dementia, primary progressive aphasia (PPA), provides important new insights
by Northwestern UniversityThe recent ability to peer into the brain of living individuals with a rare type of language dementia, primary progressive aphasia (PPA), provides important new insights
by IDIBELL-Bellvitge Biomedical Research InstituteExample of cells of a patient with advanced Alzheimer's with an altered PM20D1 gene. Credit: IDIBELLAn article published inNature Medic
by IDIBELL-Bellvitge Biomedical Research InstituteExample of cells of a patient with advanced Alzheimer's with an altered PM20D1 gene. Credit: IDIBELLAn article published inNature Medic
by Courtney Caprara,University of PittsburghIndividuals with mild cognitive impairment have a new resource in Pittsburgh with the recently establishedBrain Training and Exercise(BRiT
by Courtney Caprara,University of PittsburghIndividuals with mild cognitive impairment have a new resource in Pittsburgh with the recently establishedBrain Training and Exercise(BRiT
by University of ExeterCredit: CC0 Public DomainA new analysis shows which certain pre-existing diseases may put older people at risk of developing more severe COVID-19, implying they may need sp
by University of ExeterCredit: CC0 Public DomainA new analysis shows which certain pre-existing diseases may put older people at risk of developing more severe COVID-19, implying they may need sp
by Matthew PerroneIn this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administratio
by Matthew PerroneIn this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administratio
by University of OtagoUniversity of Otago researchers have discovered a promising new marker that could help diagnose Alzheimer's disease—and all that might be required is a simple blood test
by University of OtagoUniversity of Otago researchers have discovered a promising new marker that could help diagnose Alzheimer's disease—and all that might be required is a simple blood test
by McGill UniversityCredit: McGill UniversityFor years, neuroscientists have puzzled over how two abnormal proteins, called amyloid and tau, accumulate in the brain and damage it to cause Alzheim
by McGill UniversityCredit: McGill UniversityFor years, neuroscientists have puzzled over how two abnormal proteins, called amyloid and tau, accumulate in the brain and damage it to cause Alzheim
by Kessler FoundationCredit: Pixabay/CC0 Public DomainKessler Foundation researchers have published a novel study exploring the effects of delayed feedback on learning in individuals with moderate-to-
by Kessler FoundationCredit: Pixabay/CC0 Public DomainKessler Foundation researchers have published a novel study exploring the effects of delayed feedback on learning in individuals with moderate-to-
by University of HelsinkiCredit: Pixabay/CC0 Public DomainA study conducted at the University of Helsinki and the Helsinki University Hospital (HUS) suggests that the APOE4 allele may also increa
by University of HelsinkiCredit: Pixabay/CC0 Public DomainA study conducted at the University of Helsinki and the Helsinki University Hospital (HUS) suggests that the APOE4 allele may also increa
by Alzheimer's Research UKCredit: Pixabay/CC0 Public DomainThe pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer's drug gantenerumab did not
by Alzheimer's Research UKCredit: Pixabay/CC0 Public DomainThe pharmaceutical company Roche has announced that two phase III trials of the potential Alzheimer's drug gantenerumab did not